A Quercetin Nanocarrier‐Loaded Dual Network Injectable Hydrogel for Mesenchymal Stem Cells (MSCs) Delivery Targeting Osteoarthritis

Why It Matters

By protecting transplanted MSCs from oxidative stress and modulating joint inflammation, the hydrogel could shift OA treatment from symptom management toward disease‑modifying regeneration, addressing a massive unmet market need.

Key Takeaways

• Quercetin-loaded hydrogel improves MSC retention in osteoarthritic joints
• Antioxidant nanoparticles scavenge ROS, reducing inflammation
• Hydrogel shifts macrophages from M1 to M2 phenotype
• In rat OA model, cartilage repair and mobility improved
• Dual-network GelMA/κ-carrageenan provides self-healing, controlled degradation

Pulse Analysis

Osteoarthritis affects over 500 million people worldwide, and current interventions—painkillers, steroids, and joint replacement—primarily address symptoms rather than halting cartilage degeneration. Stem cell therapy promises tissue regeneration, yet the hostile oxidative environment of the diseased joint often compromises cell survival and engraftment. Delivering MSCs within a protective matrix that can neutralize reactive oxygen species while modulating immune responses is therefore a critical unmet need for clinicians seeking disease‑modifying solutions.

The newly engineered hydrogel combines a gelatin methacrylate (GelMA) network with κ‑carrageenan, creating a dual‑crosslinked scaffold that is injectable, self‑healing, and degrades at a controllable rate. Embedded within are quercetin‑encapsulated PLGA nanoparticles that release the flavonoid antioxidant over weeks, continuously scavenging ROS and down‑regulating inflammatory genes such as IL‑6, COX‑2, and TNF‑α. In vitro, MSCs cultured in this matrix maintain viability, exhibit heightened expression of chondrogenic markers (SOX9, COL2, ACAN), and promote M1‑to‑M2 macrophage polarization, establishing a micro‑environment conducive to cartilage repair.

Animal studies in an OA rat model confirmed the platform’s therapeutic potential: treated joints showed greater glycosaminoglycan accumulation, reduced synovial inflammation, and restored joint range of motion compared with controls. These findings suggest that integrating antioxidant nanocarriers with stem‑cell delivery could accelerate clinical translation of regenerative OA therapies. As the global OA market expands, technologies that improve cell retention and modulate inflammation are poised to attract investment and reshape standards of care, potentially reducing the reliance on costly joint replacement surgeries.